Calcitonin Gene‐Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review
Drug and Alcohol Review · 2026-05 · 45 (4)
DOI: 10.1111/dar.70178 ↗Kurz gefasst
Scoping Review in der Zeitschrift Drug and Alcohol Review, online erschienen am 19.05.2026. Verfasst von Lanfranco Pellesi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Alcoholism, Calcitonin Gene-Related Peptide, Signal Transduction. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Issue Alcohol use disorders (AUD) represent a major global health burden, and currently available pharmacological treatments show limited and heterogeneous efficacy. Calcitonin gene‐related peptide (CGRP) is a pleiotropic neuropeptide involved in stress regulation and neuroimmune signalling, and is an established therapeutic target in migraine. CGRP signalling may also be involved in alcohol‐related mechanisms, raising interest in its potential relevance for AUDs. Approach We conducted a scoping review of original studies investigating CGRP and CGRP‐related pathways in the context of alcohol exposure and AUDs. A systematic literature search was performed in PubMed, Embase, Cochrane Library, PsycINFO and Scopus. Animal and human studies published in English were included and synthesised narratively. Key Findings Thirty studies met the inclusion criteria, including 26 animal studies and 4 human studies.
Implications
Preclinical evidence indicates that CGRP plays a context‐dependent role in AUD‐related mechanisms, modulating stress‐related drinking, withdrawal‐associated adaptations and alcohol‐induced nociceptive sensitisation rather than directly driving alcohol consumption. In peripheral tissues, CGRP exerts protective effects against ethanol‐induced gastric and pulmonary injury. Human studies were limited and largely observational and showed altered CGRP biology in advanced alcohol‐related liver disease, suggesting a compensatory or homeostatic role.
Conclusions
CGRP represents a biologically relevant but complex target in AUDs, with both potential therapeutic and protective roles depending on the clinical context. Anti‐CGRP therapies may warrant exploration in carefully selected scenarios, such as alcohol‐related headache or stress‐associated symptoms during withdrawal in non‐cirrhotic patients. Given the homeostatic functions of CGRP, any pharmacological modulation should be cautiously evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology, Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Modena, Italy.
Zitieren
APA
Pellesi, L., Ahmad, T. A., & Guerzoni, S. (2026). Calcitonin Gene‐Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review. Drug and Alcohol Review, 45(4). https://doi.org/10.1111/dar.70178
Vancouver
Pellesi L, Ahmad TA, Guerzoni S. Calcitonin Gene‐Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review. Drug and Alcohol Review. 2026;45(4). doi:10.1111/dar.70178
BibTeX
@article{Pellesi2026,
author = {Pellesi, Lanfranco and Ahmad, Taibah Ali and Guerzoni, Simona},
title = {Calcitonin Gene‐Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review},
journal = {Drug and Alcohol Review},
year = {2026},
volume = {45},
number = {4},
doi = {10.1111/dar.70178}
}
EUVIMED